



Mexico City, December 30th, 2011

GENOMMA LAB ANNOUNCES ITS 2012 EARNINGS GUIDANCE

Genomma Lab Internacional S.A.B. de C.V. (BMV: LAB) (“Genomma Lab” or “the Company”) today announces its 2012 earnings guidance.

The Company expects Net Sales growth in the range of 23% to 26% and an EBITDA margin of at least 26% for the full year results of 2012.

We are making the decision of being cautious given the current uncertainty in the global market. Even though we see that consumption is recovering, in general terms, analysts expect lower economic growth in Mexico for 2012 compared with 2011, so Genomma Lab is forecasting a less strong year in 2012 than in 2011.

The main source of growth for 2012 will be our international expansion, which will be driven by our consolidation and growth in the countries where we operate, as well as by the product launches that will take place during the next year. Furthermore, our presence in the Mexican market will continue to consolidate in the over the counter (OTC) and personal care (PC) categories, and we will continue with the strategy reconfiguration of our line of branded generic products.

Company Description

Genomma Lab Internacional, S.A.B. de C.V. is one of the fastest growing pharmaceutical and personal care products companies in Latin America. Genomma Lab develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. The Company has a sound business model through a unique combination of a new product development process, consumer oriented marketing, a broad retail distribution network and a low-cost, highly flexible supply chain operating model.

Contact:

Investor Relations

Tel: +52 (55) 5081 0000 Ext. 5106

E-mail: inversion@genommalab.com

In New York: Lucía Domville/ Hugh Collins

Tel: +1 (646) 284-9400

E-mail: genommalab@grayling.com



Note on Forward-Looking Statements

This report may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like “believe,” “anticipate,” “expect,” “envisages,” “will likely result,” or any other words or phrases of similar meaning. Such statements are subject to a number of risks, uncertainties and assumptions. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this presentation and in oral statements made by authorized officers of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.